Get the Stockscreener App
11.00
24.15%
2.14
Pre-market:
10.98
-0.02
-0.18%
Cadrenal Therapeutics Inc stock is traded at $11.00, with a volume of 170.89K.
It is up +24.15% in the last 24 hours and down -8.64% over the past month.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
See More
Previous Close:
$8.86
Open:
$9.66
24h Volume:
170.89K
Relative Volume:
6.58
Market Cap:
$22.83M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-35.48
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
+17.27%
1M Performance:
-8.64%
6M Performance:
-28.99%
1Y Performance:
-15.38%
1-Day Range:
$9.66
$11.58
1-Week Range:
$8.12
$11.58
52-Week Range:
$8.12
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
11.00 | 18.39M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Why Cadrenal Therapeutics Inc. stock attracts global investorsGap Up & Fast Entry Momentum Trade Alerts - Newser
The Technical Signals Behind (CVKD) That Institutions Follow - news.stocktradersdaily.com
Is Cadrenal Therapeutics Inc. stock safe for conservative investorsSwing Trade & Daily Stock Momentum Reports - Newser
Can Cadrenal Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
Cadrenal Therapeutics appoints Dr. Lee Golden to board of directors - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Golden to Board - TipRanks
Cadrenal Therapeutics Appoints New Director - TradingView
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
Cadrenal Therapeutics, Inc. Appoints Lee Scott Golden, M.D. as Independent Director and Member of Science and Technology Committee - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - GlobeNewswire
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikes2025 Risk Factors & Real-Time Volume Spike Alerts - BỘ NỘI VỤ
Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis - MarketBeat
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosWeekly Investment Summary & Smart Allocation Stock Tips - BỘ NỘI VỤ
Precision Trading with Cadrenal Therapeutics Inc. (CVKD) Risk Zones - news.stocktradersdaily.com
Why Cadrenal Therapeutics Inc. stock could see breakout soonJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
Institutional scanner results for Cadrenal Therapeutics Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Is Cadrenal Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Safe Entry Zone Tips - newser.com
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award - The Manila Times
Agilent Technologies (NYSE: A) Debuts Altura Ultra Inert HPLC With 2x Sensitivity - Stock Titan
Detecting price anomalies in Cadrenal Therapeutics Inc. with AITreasury Yields & Fast Gaining Stock Reports - newser.com
What the charts say about Cadrenal Therapeutics Inc. todayWatch List & Daily Stock Trend Watchlist - newser.com
Is Cadrenal Therapeutics Inc. stock attractive for retirement portfolios2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Cadrenal Therapeutics Receives Legal Opinion From Blank Rome LLP On ?Validity Of Share Offering - MarketScreener
Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks
Cadrenal Therapeutics IncBlank Rome LLP issued legal opinion on $3,438,062 sharesSEC filing - MarketScreener
[8-K] Cadrenal Therapeutics, Inc. Reports Material Event | CVKD SEC FilingForm 8-K - Stock Titan
Price momentum metrics for Cadrenal Therapeutics Inc. explainedDividend Hike & AI Forecast for Swing Trade Picks - newser.com
Quantitative breakdown of Cadrenal Therapeutics Inc. recent move2025 Major Catalysts & Growth Focused Entry Reports - newser.com
What institutional flow reveals about Cadrenal Therapeutics Inc.Insider Selling & Verified Entry Point Signals - newser.com
Combining machine learning predictions for Cadrenal Therapeutics Inc.July 2025 Review & Capital Protection Trading Alerts - newser.com
Is Cadrenal Therapeutics Inc. stock cheap compared to fundamentalsJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
Will Cadrenal Therapeutics Inc. stock outperform value stocksWeekly Investment Recap & Technical Entry and Exit Tips - Fundação Cultural do Pará
What to do if you’re stuck in Cadrenal Therapeutics Inc.2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):